Syneron Bio

Syneron Bio (元思生肽) is a biotechnology company dedicated to developing novel macrocyclic peptide drugs. The company has established a rich and differentiated pipeline of macrocyclic peptide drugs using its proprietary Synova™ platform technology, providing breakthrough therapeutic solutions for patients in the global oncology and chronic disease fields. The core team of Syneron Bio possesses extensive experience in drug development and world-class data science capabilities. Within less than three years, the company completed multiple rounds of equity financing, with investors including several well-known venture capital funds.